MedTrace Logo

Trial to Assess the Efficacy of Neuroprotective Drugs Administered Topically to Prevent or Arrest Diabetic Retinopathy

NCT01726075 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 450

Last updated 2016-01-12

No results posted yet for this study

Summary

To assess whether neuroprotective drugs administered topically (somatostatin and brimonidine) are able to prevent or arrest the development and progression of neurodegenerative changes

Conditions

Interventions

DRUG

COLIRIOBCN070660

One drop per eye twice a day during 24 months

DRUG

Placebo

One drop per eye twice a day during 24 months

DRUG

Brimonidine

One drop per eye twice a day during 24 months

Sponsors & Collaborators

  • BCN Peptides

    lead INDUSTRY

Principal Investigators

  • José Cunha-Vaz, Prof. · Association for Innovation and Biomedical Research on Light and Image

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • Denmark
  • France
  • Germany
  • Italy
  • Portugal
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01726075 on ClinicalTrials.gov